Form 8-K - Current report:
SEC Accession No. 0001193125-23-160744
Filing Date
2023-06-05
Accepted
2023-06-05 16:31:04
Documents
14
Period of Report
2023-05-28
Items
Item 2.05: Cost Associated with Exit or Disposal Activities
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 5.07: Submission of Matters to a Vote of Security Holders
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d441631d8k.htm   iXBRL 8-K 44055
2 EX-99.1 d441631dex991.htm EX-99.1 17149
6 GRAPHIC g441631g23p23.jpg GRAPHIC 2155
  Complete submission text file 0001193125-23-160744.txt   200045

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA rain-20230528.xsd EX-101.SCH 2856
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE rain-20230528_lab.xml EX-101.LAB 18737
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE rain-20230528_pre.xml EX-101.PRE 11711
8 EXTRACTED XBRL INSTANCE DOCUMENT d441631d8k_htm.xml XML 3461
Mailing Address 8000 JARVIS AVENUE SUITE 204 NEWARK CA 94560
Business Address 8000 JARVIS AVENUE SUITE 204 NEWARK CA 94560 (510) 953-5559
Rain Oncology Inc. (Filer) CIK: 0001724979 (see all company filings)

EIN.: 821130967 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40356 | Film No.: 23992985
SIC: 2834 Pharmaceutical Preparations